357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)S. Nucera, Daniele Generali, F. Schettini et al.|Annals of Oncology|2024Cited by 0
209P Comparative analysis of clinician and AI decision-making in HR+/HER2- early breast cancer within routine clinical practice and clinical trialR. Buonaiuto, Mario Giuliano, Rossana Di Rienzo et al.|ESMO Open|2025Cited by 0
124P Risk stratification in HR+/HER2- EBC: A comparative study of Prosigna and Oncotype DX with emphasis on menopausal status and lymph node involvementGiulia Cursano, Nicola Fusco, Francesco Conversano et al.|ESMO Open|2025Cited by 0